A new biomarker - index of Cardiac Electrophysiological Balance (iCEB) - plays an important role in drug-induced cardiac arrhythmias: Beyond QT-prolongation and Torsades de Pointes (TdPs)

Journal of Pharmacological and Toxicological Methods

Volumn 68, Issue 2, 2013, Pages 250-259

  Lu, Hua Rong ^a   Yan, Gan Xin ^b   Gallacher, David J ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

Drug induced arrhythmias; ICEB (index of Cardiac Electrophysiological Balance); QRS; QT; TdPs: Torsades de Pointes; VT VF: ventricular tachycardia fibrillation

Indexed keywords

DEXTROPROPOXYPHENE; DIGOXIN; DOFETILIDE; ENCAINIDE; ISOPRENALINE; LEMAKALIM; NS 1643; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARDIOVASCULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART VENTRICLE CONDUCTION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; INDEX OF HEART ELECTROPHYSIOLOGICAL BALANCE; NONHUMAN; PREDICTION; QT INTERVAL; QT PROLONGATION; RABBIT; RISK ASSESSMENT; T WAVE; TORSADE DES POINTES;

ORYCTOLAGUS CUNICULUS;

BASIC CYCLE LENGTHS; BCL; CARDIAC ARRHYTHMIA SUPPRESSION TRIAL; CAST; COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS; CONDUCTION VELOCITY; CPMP; CV; DIMETHYL SULPHOXIDE; DMSO; DRUG-INDUCED ARRHYTHMIAS; E14; EAD; EARLY AFTERDEPOLARIZATION; ECG; EFFECTIVE REFRACTORY PERIOD; ELECTROCARDIOGRAM; ERP; HERG; HUMAN ETHER-À-GO-GO-RELATED GENE; I(KR); I(KS); I(NA); ICEB; ICEB (INDEX OF CARDIAC ELECTROPHYSIOLOGICAL BALANCE); ICH; ICH HARMONIZED TRIPARTITE GUIDELINE E14: THE CLINICAL EVALUATION OF QT/QTC INTERVAL PROLONGATION AND PROARRHYTHMIC POTENTIAL FOR NON-ANTIARRHYTHMIC DRUGS; INDEX OF CARDIAC ELECTROPHYSIOLOGICAL BALANCE; LAMBDA; MAP; MAXIMAL TRANSMURAL DISPERSION OF REPOLARIZATION; MONOPHASIC ACTION POTENTIAL; QRS; QT; SODIUM CURRENT; T WAVE PEAK-TWAVE END (MEASUREMENT OF TRANSMURAL DISPERSION); TDPS; TDPS: TORSADES DE POINTES; TDR; THE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE; THE RAPIDLY ACTIVATING DELAYED RECTIFIER POTASSIUM CURRENT; THE SLOWLY ACTIVATING COMPONENT OF DELAYED RECTIFIER POTASSIUM CURRENT; TORSADES DE POINTES; TP-TE; VENTRICULAR FIBRILLATION; VENTRICULAR TACHYCARDIA; VF; VT; VT/VF: VENTRICULAR TACHYCARDIA/FIBRILLATION; Λ;

ANIMALS; BIOMARKERS, PHARMACOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; LONG QT SYNDROME; MALE; RABBITS; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 84882917806     PISSN: 10568719     EISSN: 1873488X     Source Type: Journal    
DOI: 10.1016/j.vascn.2013.01.003     Document Type: Article

References (59)

1. Aidonidis I., Poyatzi A., Stamatiou G., Lymberi M., Stamatoyannis N., Molyvdas P.A. Dose-related shortening of ventricular tachycardia cycle length after administration of the KATP channel opener bimakalim in a 4-day-old chronic anesthetized pig model. Journal of Cardiovascular Pharmacology and Therapeutics 2009, 14:2222-2230.
2. Anttonen O., Vaananen H., Junttila J., Huikuri H.V., Viitasalo M. Electrocardiographic transmural dispersion of repolarizarion in the patients with inherited short QT syndrome. Annals of Noninvasive Electrocardiology 2008, 13:295-300.
3. Antzelevitch C. Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes. AJP Heart 2007, 293:H2024-H2038.
4. Antzelevitch C., Viskin S., Shimizu A., Yan G.-X., Kowey P., Zhang L., et al. Does Tpeak-Tend provide an index of transmural dispersion of repolarization?. Heart Rhythm 2007, 4:1114-1119.
5. Balasubramaniam R., Grace A.A., Saumarez R.C., Vandenberg J.I., Huang C.L. Electrogram prolongation and nifedipine-suppressible ventricular arrhythmias in mice following targeted disruption of KCNE1. Journal de Physiologie 2003, 552:535-546.
6. 90 ex vivo, but is associated with increased risk of arrhythmias. Acta Physiologica 2010, 198(Suppl. 677). O-MON-2-6.
7. The CAST Investigators Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The New England Journal of Medicine 1989, 321:406-412.
8. Cravey R.H., Shaw R.F., Nakmura G.R. Incidence of propoxyphene poising: A report of fetal cases. Journal of Forensic Sciences 1974, 19:72-80.
9. Cubeddu L.X. QT prolongation and fatal arrhythmias: A review of clinical implications and effects of drugs. American Journal of Therapeutics 2003, 10:452-457.
10. Echt D.S., Liebson P.R., Mitchell L.B., Peters R.W., Obias-Manno D., Barker A.H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmias Suppression Trial. The New England Journal of Medicine 1991, 324:781-788.
11. Extramiana F., Antzelevitch C. Amplified transmurale dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation 2004, 110:3661-3666.
12. Food and Drug Administration, HHS International Conference on Harmonisation; Guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Federal Register 2005, 70:61133-61134.
13. Gaita F., Giustetto C., Bianchi F., Wolpert C., Schimpf R., Riccardi R., et al. Short QT syndrome. A familial cause of sudden death. Circulation 2003, 108:965-970.
14. Gintant G.A., Gallacher D.J., Pugsley M.K. The "overly-sensitive" heart sodium channel block and QRS interval prolongation. British Journal of Pharmacology 2011, 164:254-259.
15. Girouard S.D., Pastore J.M., Laurita K.R., Gregory K.W., Rosenbaum D.S. Optical mapping in new guinea-pig model of ventricular tachycardia reveals mechanisms for multiple wavelengths in a single reentrant circuit. Circulation 1996, 93:603-613.
16. Girouard S.D., Rosenbaum D.S. Role of wavelength adaptation in the initiation, maintenance, and pharmacologic suppression of reentry. Journal of Cardiovascular Electrophysiology 2001, 12:697-707.
17. Giustetto C., Schimpf R., Mazzanti A., Scrocco C., Maury P., Anttonen O., et al. Long-term follow-up of patients with short QT syndrome. Journal of the American College of Cardiology 2011, 58:587-595.
18. + channel and drug-induced prolongation of the QRS complex. British Journal of Pharmacology 2011, 164:260-273.
19. Heist E.K., Ruskin J.N. Contemporary reviews in cardiovascular medicine. Drug-induced arrhythmia. Circulation 2010, 122:1426-1435.
20. Hondeghem L.M., Dujardin K., Hoffmann P., Dumotier B., De clerk F. Drug-induced QTc prolongation dangerously underestimates proarrhythmic potential: Lessons from terfenadine. Journal of Cardiovascular Pharmacology 2011, 57:589-597.
21. ICH Hamonized Tripartite Guideline (E14) The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs 2005, Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/Step4/E14_Guideline.pdf.
22. Jacobson I., Carlsson L., Duke G. Beat by Beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetized methoxamine-sensitized rabbit. Journal of Pharmacological and Toxicological Methods 2011, 63:40-46.
23. Kashani A., Barold S.S. Significance of QRS complex duration in patients with heart failure. Journal of the American College of Cardiology 2005, 46:2183-2192.
24. Kennedy R.H., Seifen E., Akera T., Brody T.M. Effects of bay K-8644 on inotropic and arrhythmogenic actions of digoxin. European Journal of Pharmacology 1986, 124:11-20.
25. Laverty H., Benson C., Cartwright E., Cross M., Garland C., Hammond T., et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?. British Journal of Pharmacology 2011, 163:675-693.
26. Lenz T.L., Hilleman D.E. Dofetilide: A new antiarrhythmic agent approved for conversion and/or maintenance of atrial fibrillation/atrial flutter. Drugs of Today 2000, 36:759-771.
27. Liu T.G., Brown B.S., Wu Y., Antzelevitch C., Kowey P.R., Yan G.X. Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 2006, 3:948-956.
28. Liu H., Yang L., Jin M.W., Sun H.Y., Huang Y., Li G.R. The selective estrogen receptor modulator raloxifene inhibits cardiac delayed rectifier potassium currents and voltage-gated sodium current without QTc interval prolongation. Pharmacological Research 2010, 62:384-390.
29. Lu H.R., Vlaminckx E., Van de Water A., Gallacher D.J. Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit Purkinje fibers: Importance of beat-to-beat instability of the repolarization. Journal of Cardiovascular Electrophysiology 2006, 17:415-422.
30. Lu H.R., Vlaminckx E., Hermans A., Rohrbacher J., Van Ammel K., Towart R., et al. Predicting drug-induced changes in Qt interval and arrhythmias: QT-shortening drugs point to gaps in the ICHS7B guideline. British Journal of Pharmacology 2008, 154:1427-1438.
31. Lu H.R., Rohrbacher J., Vlaminckx E., Van Ammel K., Yan G.-X., Gallacher D.J. Predicting drug-induced lowing of conduction and proarrhythmias: Identifying the "bad" sodium channel blockers. British Journal of Pharmacology 2010, 160:60-76.
32. Lu H.R., Hermans A.N., Gallacher D.J. Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de pointes?. British Journal of Pharmacology 2012, 166:1490-1502.
33. Madias J.E. Drug-induced QRS morphology and duration changes. Cardiology Journal 2008, 15:505-509.
34. Mines G.R. On dynamic equilibrium in the heart. Journal of Physiology (London) 1913, 46:349-383.
35. Nattel S. Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovascular Research 1998, 37:567-577.
36. Nam G.B., Burashnikov A., Antzelevitch C. Cellular mechanisms underlying the development of catacholaminergic ventricular tachycardia. Circulation 2005, 111:2727-2733.
37. Psaty B.M., Furberg C.D. Rosiglitazone and cardiovascular risk. The New England Journal of Medicine 2007, 356:2522-2524.
38. Pugsley M.K., Authier S., Curtis M.J. Principles of safety pharmacology. British Journal of Pharmacology 2008, 154:1382-1399.
39. Redfern W.S., Ewart L., Hammond T.G., Bialecki R., Kinter L., Lindgren S., et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 2010, 114:1081.
40. Redfern W.S., Valentin J.-P. Trends in safety pharmacology: Posters presents at the annual meetings of the safety pharmacology society 2001-2010. Journal of Pharmacological and Toxicological Methods 2011, 64:102-110.
41. 2+ loading and improved functional recovery after ischemia reperfusion injury in old vs young guineapig hearts. American Journal of Physiology - Heart and Circulatory Physiology 2012, 302:H855-H863.
42. Robert E., Bruelle P., de la Coussaye J.E., Juan J.M., Brugada J., Peray P., et al. Electrophysiologic and proarrhythmogenic effects of therapeutic and toxic doses of imipramine; A study with high resolution ventricular epicardial mapping in rabbit hearts. Journal of Pharmacology and Experimental Therapeutics 1996, 278:170-178.
43. Robert E., Aya A.G., de la Coussaye J.E., Peray P., Juan J.M., Brugada J., et al. Dispersion-based reentry: Mechanism of initiation of ventricular tachycardia in isolated rabbit hearts. American Journal of Physiology 1999, 276:H413-H423.
44. Roden D.M. Drug-induced prolongation of the QT interval. The New England Journal of Medicine 2004, 350:1013-1022.
45. Sellers T.D., DiMacro J.P. Sinusoidal ventricular tachycardia associated with flecainide acetate. Chest 1984, 85:647-649.
46. Sicouri S., Moro S., Litovsky S., Elizari M.V., Antzelevitch C. Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. Journal of Cardiovascular Electrophysiology 1997, 8:1269-1279.
47. Shah R.R. Pharmacogenetic aspects of drug-induced torsade de pointes: Potential tool for improving clinical drug development and prescribing. Drug Safety 2004, 27:145-172.
48. Shah R.R. Drug-induced QT interval shortening: potential harbinger of proarrhythmias and regulatory perspective. British Journal of Pharmacology 2010, 159:58-69.
49. Song Y., Wu L., Shryock J.C., Belardinelli L. Selective attenuation of isoprenaline-stimulated arrhythmias activity by a partial agonist of adenosine A1 receptor. Circulation 2002, 105:118-123.
50. Thomsen M.B., Verduyn S.C., Stengl M.S., Beekman J.D.M., de Pater G., van Opstal J., et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004, 110:2453-2459.
51. Watanabe H., Knollmann B.C. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy. Journal of Electrocardiology 2011, 44:650-656.
52. Yan G.X., Shimizu W., Antzelevitch C. Characteristics and distribution of M Cells in arterially perfused canine left ventricular wedge preparations. Circulation 1998, 98:1921-1927.
53. Yan G.X., Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 1999, 100:1660-1666.
54. Yan G.X., Rials S.J., Wu Y., Liu T., Xu X., Marinchak R.A., et al. Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. American Journal of Physiology - Heart and Circulatory Physiology 2001, 281:H1968-H1975.
55. Yan G.X., Lankipalli R.S., Burke J.F., Musco S., Kowey P.R. Ventricular repolarization components on the electrocardiogram: Cellular basis and clinical significance. Journal of the American College of Cardiology 2003, 42:401-409.
56. Ulens C., Daenens P., Tygat J. Norpropoxyphene-induced cardiotoxicity is associated with changes in ion-selectivity and gating of HERG currents. Cardiovascular Research 1999, 44:568-578.
57. Van der Linde H., Van de Water A., Loots W., Van Deuren B., Lu H.R., Van Ammel K., et al. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anaesthetized dogs. Journal of Pharmacological and Toxicological Methods 2005, 52:168-177.
58. Ohkubo K., Watenabe I., Okumura Y., Ashino S., Kofune M., Nagashima K., et al. Prolonged QRS duration in lead V2 and risk of life-threatening ventricular arrhythmias in patients with Brugada syndrome. International Heart Journal 2011, 52:98-102.
59. Wu Y., Carlsson L., Liu T., Kowey P.R., Yan G.-X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. Journal of Cardiovascular Electrophysiology 2005, 16:898-904.